Stockwinners Market Radar for September 08, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:27 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Nissan Motor (NSANY) CEO Hiroto Saikawa has decided to step down days after admitting he received improperly inflated compensation, according to Nikkei Asian Review. Saikawa has told several Nissan executives of his intent, the publication noted, adding that the exact date of his resignation and his replacement are yet to be decided. 2. Boeing (BA) announced it had suspended load testing of its new widebody 777X aircraft as media reports said a cargo door failed in a ground stress test, according to Reuters. "During final load testing on the 777X static test airplane, the team encountered an issue that required suspension of the test," Boeing spokesman Paul Bergman said in a statement. 3. This past Thursday, Lululemon (LULU) reported blowout financial results that sent its stock 8% higher the next day, as the athleisure trend becomes a lasting consumer shift, not a fad, Jack Hough writes in this week's edition of Barron's. More gains for comfortable fabrics should be expected, the author adds. 4. AT&T (T) subsidiary Warner Bros.' "It: Chapter Two" opened to $91M domestically as it became the second-best horror showing of all times. Overseas, the pic earned an estimated $94M from 75 markets for $185M globally. The sequel received a B+ CinemaScore and 67% on Rotten Tomatoes. 5. AT&T, D.R. Horton (DHI), McKesson (MCK), Balfour Beatty (BAFYY) saw positive mentions in this week's edition of Barron's.

15:24 EDT Ipsen, Servier announce initial data from Phase II/III RESILIENT study - Ipsen and Servier announced initial safety and efficacy data from Part 1 of the Phase II/III RESILIENT study of investigational liposomal irinotecan in patients with small cell lung cancer who progressed following a first-line platinum-based regimen. The results, which included preliminary safety and efficacy data, were presented as an oral presentation at the IASLC 2019 World Conference on Lung Cancer. The RESILIENT trial is a randomized, open-label two-part Phase II/III study assessing the safety, tolerability and efficacy of investigational liposomal irinotecan as a monotherapy for SCLC patients who have progressed on or after a first-line platinum-based regimen. The trial is being conducted in two parts. Part 1 includes dose-finding and dose-escalation analyses to determine the appropriate dose of study drug where the primary endpoints are safety and tolerability. Part 2 has just been initiated with the first patients randomized and will focus on efficacy assessments versus the current standard of care, topotecan, including progression-free survival and overall survival. ONIVYDE is a topoisomerase inhibitor featuring a liposomal formulation of irinotecan that is designed to prolong its circulation before conversion to its active form. This unique mechanism of delivery was evaluated in the NAPOLI-1 Phase III study, which led to the U.S. Food and Drug Administration and European Medicines Agency approval of ONIVYDE in combination with fluorouracil and leucovorin for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy. ONIVYDE is not indicated as a single agent for the treatment of patients with metastatic adenocarcinoma of the pancreas.